1.24
6.06%
-0.08
After Hours:
1.24
Ocugen Inc stock is currently priced at $1.24, with a 24-hour trading volume of 7.66M.
It has seen a -6.06% decreased in the last 24 hours and a -24.39% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $1.32 pivot point. If it approaches the $1.22 support level, significant changes may occur.
Ocugen Inc Stock (OCGN) Financials Data
Ocugen Inc (OCGN) Net Income 2024
OCGN net income (TTM) was -$75.52 million for the quarter ending September 30, 2023, a -2.07% decrease year-over-year.
Ocugen Inc (OCGN) Cash Flow 2024
OCGN recorded a free cash flow (TTM) of -$77.44 million for the quarter ending September 30, 2023, a -32.17% decrease year-over-year.
Ocugen Inc (OCGN) Earnings per Share 2024
OCGN earnings per share (TTM) was -$0.33 for the quarter ending September 30, 2023, a +5.71% growth year-over-year.
Ocugen Inc Stock (OCGN) Latest News
Alphabet To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Monday
Benzinga
Key Takeaways From Ocugen Analyst Ratings
Benzinga
Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
GlobeNewswire Inc.
Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets
GlobeNewswire Inc.
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
GlobeNewswire Inc.
Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study
Zacks Investment Research
About Ocugen Inc
Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The company offers an ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules, as well as targets a range of retinal and ocular surface diseases. Its pipeline includes OCU400 and OCU410 for the treatment of inherited retinal disorders; OCU200 for the treatment of wet-AMD, DME, and diabetic retinopathy; OCU100 for retinitis pigmentosa; and OCU300, which is in Phase III clinical trial for the treatment of ocular graft versus host diseases. The company has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing. Ocugen, Inc. is based in Malvern, Pennsylvania.
Cap:
|
Volume (24h):